Skip to main content

New Potential Biomarker Discovered for Treatment of Deadly Prostate Cancer

After a successful initial response to prostate cancer treatment targeting the androgen receptor, some patients develop neuroendocrine prostate cancer (NEPC), which is the deadliest subtype of castration-resistant prostate cancer and does not have an effective treatment. In a new study, researchers from the Sanford Burnham Prebys Medical Discovery Institute (SBP) found that protein kinase C lambda/iota (PKCλ/ι) causes metabolic reprogramming that creates favorable conditions for NEPC to grow. Th...

Continue reading